Pluri

Company Overview

Snapshot

Founded in January 2003, Pluri operates with 201–500 employees and has raised a total of $139.4M across 14 funding rounds. The company went public on NASDAQ in April 2003 and on TASE in December 2010. In January 2025, Pluri acquired Kokomodo, expanding its strategic footprint.

Business overview

Pluri develops cell-based products aimed at promoting global well-being and sustainability across various applications. The company leverages a patented and validated 3D cell expansion system to advance novel cell-based solutions for regenerative medicine, food technology, and other industries. Its technology platform is designed for accurate, scalable, cost-effective, and consistent mass cell production, serving markets that require effective cell-based solutions.

Strategic signal

Pluri's strategic collaboration with Instituto del Café de Chiapas in October 2025, through its subsidiary Coffeesai, to advance cell-based coffee manufacturing in Mexico signals a significant move into the food technology sector. This partnership demonstrates the company's commitment to diversifying its applications beyond regenerative medicine and leveraging its core 3D cell-based technology for sustainable food production, indicating potential for new revenue streams and market expansion.

Company Intelligence Q&A

What was Pluri's most recent acquisition?

In January 2025, Pluri acquired Kokomodo, a move that expanded its operational capabilities.

What was Pluri's latest funding activity?

In December 2025, Pluri completed a PIPE funding round. This followed another PIPE round in February 2025, and a PIPE round in January 2025 led by Alejandro Weinstein.

What is Pluri's involvement in the food technology sector?

In October 2025, Pluri's subsidiary Coffeesai announced a strategic collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. This initiative highlights Pluri's application of its cell-based technology to address food scarcity and sustainability.

What is Pluri's strategic focus in cancer treatment?

In October 2024, Pluri collaborated with Bar-Ilan University to advance cancer immunotherapy for solid tumors, supported by the Israel Innovation Authority. Additionally, in May 2024, Pluri launched a novel immunotherapy platform leveraging MAIT cells for solid tumor cancer treatment.

What was Pluri's financial performance in the first quarter of 2025?

In November 2024, Pluri reported a loss of US$1.08 per share for the first quarter of 2025, compared to a US$0.96 loss in the first quarter of 2024.